Peter Soelkner, who will head up VPI, explained that: “The formation of VPI allows us to better position ourselves as a worldwide leader in pre-filled aseptic injection solutions.
"By creating an entity that focuses exclusively on sales, marketing and customer service on a global level, Vetter will move significantly closer to the international market and can build even stronger relationships with our clients and prospects throughout the world," continued Soelkner.
VPF, which is based in Ravensburg, Germany, will now focus exclusively on the company's manufacturing and pharmaceutical operations designed to support clients’ needs for aseptically pre-filled injectable products, from clinical development to market launch.
"By realigning our resources to empower each entity's core competencies, both VPI and VPF alike can be major catalysts in Vetter's continued growth and expansion in the years to come no matter how much the industry may change," added Soelkner.
Vetter's development services division provides support for its pharmaceutical and biotech clients in the early stages of development, from clinical phases and regulatory approval to worldwide product launch. On the other hand the firm's commercial manufacturing unit handles the entire production process, from compounding and aseptic filling to the final packaging of a product.
Aseptic filling is one of the areas that has seen the most growth in the pharmaceutical outsourcing sector in recent years as drugmakers keen to enter the lucrative markets have sought ways to reduce the cost of such operations.